Methylprednisolone prevents tumour necrosis factor- -dependent multinucleated giant cell formation

Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?

For many years glucocorticoids (GCs) have been known to effectively suppress the clinical manifestations of giant cell arteritis (GCA), and prevent its ischaemic complications. GCs are still the treatment of choice for this disease. It is recommended that GC therapy be commenced as soon as the diagnosis of GCA is established. An initial dose of 40–60 mg/daily of prednisone (or equivalent) as a ...

Bone: Giant cell tumour

Rib Giant Cell Tumour

A 55 year old woman was admitted because of a slowly growing chest mass. A diagnosis of giant cells tumor (GCT) was made. In sharp contrast to other large bone metaphysis it accounts for < 1 % of all primary rib’s neoplasias. The resection included one normal adjacent rib above and below the tumour with all intervening intercostals muscles and pleura and the adjacent cartilages. Reconstruction ...

Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.

Many biological functions are regulated through interactions of extracellular molecules with their cognate cell surface receptors. The transduction of these signals by their receptors at the plasma membrane to the intracellular machinery results in such cellular activities as gene activation, protein phosphorylation, cell proliferation, and cell destruction. Though the kinetics of these activit...

IL-4 induces the formation of multinucleated giant cells and expression of β5 integrin in central giant cell lesion

BACKGROUND It is now well established that IL-4 has a central role in the development of monocytes to multinucleated giant cells (MGCs) by inducing the expression of integrins on the surface of monocytes. The aim of this study was to investigate the potential role of IL-4 in induction of β5 integrin expression in the peripheral blood samples of patients with giant cell granuloma. MATERIAL AND...